Region Hovedstadens Psykiatriske

Researchers at the Mental Health Center Glostrup are investigating biological biomarkers that may predict how patients with schizophrenia respond to clozapine treatment, aiming to move toward more personalized care.

• Identification of predictive biomarkers for clozapine efficacy
• Correlation of biomarker profiles with clinical outcomes
• Development of tools for individualized treatment decisions

This work supports the site’s broader focus on improving outcomes for individuals living with severe mental disorders.

A follow‑up study is collecting extended safety data on patients with cognitive impairment due to schizophrenia who previously received Iclepertin, to ensure the therapy remains well‑tolerated over time.

• Monitoring adverse events beyond the initial treatment phase
• Assessing impact on cognitive function and daily living
• Comparing long‑term safety with placebo outcomes

The investigation reflects the center’s commitment to safe, effective interventions for cognitive deficits in mental illness.

The TOTEMS trial examines how the investigational compound GT‑002, a partial GABA(A)-receptor modulator, influences brain activity and cognitive impairment in patients across the schizophrenia spectrum.

• Measurement of event‑related EEG and EMG responses
• Evaluation of hypofrontality as a mechanistic marker
• Short‑term effects on attention, memory, and processing speed

Findings may guide new strategies to address the persistent cognitive challenges faced by many individuals with psychotic disorders.

In the AMEND study, researchers are testing whether adding memantine to standard antipsychotic therapy can lessen negative symptoms in patients experiencing a first episode psychosis.

• Reduction of anhedonia, avolition, and social withdrawal
• Exploration of glutamate system modulation alongside dopamine blockade
• Assessment of functional recovery and quality of life

This approach seeks to improve early treatment outcomes for young adults confronting psychotic illness.

A phase‑3 investigation evaluates the efficacy of KarXT combined with mood stabilizers (lithium, valproate, or lamotrigine) in reducing the severity of acute mania, with or without mixed features, in bipolar‑I disorder patients.

• Comparison of mania severity scores between KarXT and placebo groups
• Monitoring of safety and tolerability alongside standard mood stabilizers
• Exploration of rapid symptom relief and functional improvement

Success could expand therapeutic options for individuals struggling with severe mood episodes.